Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
JXL069
AOB14546B
CAS: 2260696-63-5
Chemical Name: (E)-3-(1-(3,5-Bis(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-cyanoacrylic acid
961 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | 100 mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $80.75 | Total: $403.75 |
| 1 | 10 | $68.40 | Total: $684.00 |
| 1 | 25 | $57.95 | Total: $1,448.75 |
| 1 | 50 | $49.40 | Total: $2,470.00 |
| 1 | 100 | $42.75 | Total: $4,275.00 |
Overview
Novel potent mitochondrial pyruvate carrier (MPC) inhibitor to treat hair loss
Functional Overview of JXL069
1. Potent and Selective Inhibition of Mitochondrial Pyruvate Carrier (MPC)
JXL069 is a highly selective and effective inhibitor of the mitochondrial pyruvate carrier (MPC), which plays a critical role in transporting pyruvate—the key product of glycolysis—into the mitochondria. By inhibiting MPC, JXL069 blocks this mitochondrial entry, redirecting cellular metabolism toward glycolysis.Wikipedia
2. Inhibitory Potency (IC₅₀ Values)
Reports an IC₅₀ value of 42.8 nM for JXL069 as an MPC inhibitor.
In other biochemical assays, particularly involving MPC1/2-mediated pyruvate transport, the IC₅₀ is approximately 0.53 µM.
3. Metabolic and Biological Effects
Metabolic Shift: By hindering pyruvate import, JXL069 forces cells to rely more on glycolysis instead of mitochondrial oxidative phosphorylation.World Mitochondria Society
Hair Follicle Stem Cell Activation: This metabolic switch is biologically significant in hair biology—JXL069 stimulates dormant hair follicle stem cells (in the telogen phase) to re-enter the active growth phase (anagen), enhancing hair growth in preclinical models.WikipediaWorld Mitochondria Society
4. Therapeutic Research Applications
Hair Loss (Alopecia): Originally developed at the University of California, JXL069 is being investigated for androgenetic alopecia. Related compounds, including a candidate named PP405, are now in Phase II clinical trials as topical scalp treatments.Wikipedia
Oncology and Metabolic Disease Research: MPC inhibitors like JXL069 are also valuable for studying cancer metabolism and metabolic disorders, offering potential therapeutic avenues in these areas.World Mitochondria Society
5. Structure–Activity Relationship (SAR) Insights
JXL069 features a 7-azaindole heterocycle, and SAR studies show it exhibits stronger MPC inhibition than related analogues containing 4- or 6-azaindole cores or traditional indole cores like JXL020.PMCUCLA Chemistry
Chemical Properties
| Molecular Formula | C20H21F6N3O2 |
| Molecular Weight | 439.32 |
| CAS Numbers | 2260696-63-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | (E)-3-(1-(3,5-Bis(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-cyanoacrylic acid |
| InChl Key | IGVIZFSCSSEYDA-WUXMJOGZSA-N |
| InChl Code | InChI=1S/C20H11F6N3O2/c21-19(22,23)14-4-11(5-15(7-14)20(24,25)26)9-29-10-13(6-12(8-27)18(30)31)16-2-1-3-28-17(16)29/h1-7,10H,9H2,(H,30,31)/b12-6+ |
| SMILES Code | FC(C1=CC(C(F)(F)F)=CC(CN2C=C(/C=C(C(O)=O)C#N)C3=CC=CN=C32)=C1)(F)F |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Synonyms
JXL 069; JXL-069
References
1) Xiaoguang Liu et al., Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss, J. Med. Chem. 2021, 64, 4, 2046–2063